Author: Younes, Younes R; Stockley, Susan; Keegan, Lorna; O'Donoghue, Linda; Yohannan, Elizabeth; Read, Liz; Williamson, Jamie-Leigh; Peter, John; Lakshmipathy, Kavitha; Smout, Vera; Nayyar, Vidhu; Emmanuel, Julian; Zachariah, Sunil; Clark, James; Field, Benjamin C T
Title: COVID-19 and dexamethasone-induced hyperglycaemia: workload implications for diabetes inpatient teams Cord-id: lpbimeb3 Document date: 2021_1_1
ID: lpbimeb3
Snippet: The RECOVERY trial showed that mortality in patients requiring supplementary oxygen or ventilation for COVID-19 is reduced by administration of dexamethasone 6 mg daily for up to 10 days [1]. This welcome finding led to an increased frequency of dexamethasone use at our district general hospital. However, high-dose glucocorticoid exposure is a well-recognised cause of hyperglycaemia, particularly in the presence of diabetes [2-7]. Furthermore, glucocorticoid-induced hyperglycaemia is associated
Document: The RECOVERY trial showed that mortality in patients requiring supplementary oxygen or ventilation for COVID-19 is reduced by administration of dexamethasone 6 mg daily for up to 10 days [1]. This welcome finding led to an increased frequency of dexamethasone use at our district general hospital. However, high-dose glucocorticoid exposure is a well-recognised cause of hyperglycaemia, particularly in the presence of diabetes [2-7]. Furthermore, glucocorticoid-induced hyperglycaemia is associated with an increased risk of mortality, infections, and cardiovascular events [8]. Guidelines have been developed to address these risks, both in the general inpatient setting and specifically in the context of COVID-19 [9-10].
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date